Clinical Trial Search

Primary: Percent Change From Baseline in Villous Height to Crypt Depth Ratio (VH:CD) at Week 12 — -62.66; -53.78; -60.17 percent change — p=0.7271

Primary: dCA Measurement During Acute Changes in Mean Arterial Pressure, TCD — 0.262 per second

Primary: Number of Participants Who Have Died From Cardiovascular Disease Since the End of the ASCOT Study

Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale

Primary: Post Operative Opioid Usage — 2.25; 4 morphine equivalent

Primary: Incident Rates of Definite Pulmonary Tuberculosis (TB) Disease, Not Associated With HIV-infection, Meeting the Case Definition 1 — 0.3; 0.6 cases per 100 person-years…

Primary: Number of Subjects With Post-Operative Persistent Pain (PPP) — 211; 34 Participants

Primary: Number of Ambulatory Patch Monitor Participants Having Significant Symptomatic Arrhythmia — 9 Participants

Primary: Action Plan Initiation Survey (APIS-5) — 53; 14 Participants — p=0.006

Primary: Percent Change in Serum Thromboxane B2 — 97.0; 97.4; 98.3; 96.7 Percent inhibition of baseline — p=>0.05

Primary: Median Change From Baseline to Week 7, of Interferon (IFN) and Interferon Gamma (IFN-gamma) Inducible Factors — 0.0130; 0.0320; 0.2310; 0.1600 pg/mL

Primary: Changes in Serum Levels of Vitamin D [25(OH)D3] in Subjects in the Supplementation Group and Those in the Control Group (Placebo). — 29.8; 34.8; 46.94; 29.6 ng/ml

Primary: Estimated Blood Loss (EBL) — 3116; 9420 cc

Primary: Annualized Total Bleeding Rate of Individually Tailored Prophylaxis — 4.67; 58.08 Bleeding events per year (ABR) — p=<0.0001

Primary: Brief Symptom Inventory and Burden Interview — 6.2; 6.1; 6; 5.9 units on a scale